Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases
Open accessThe DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Abstract
Receptor-interacting serine/threonine kinase 2 (RIPK2) is a vital immunomodulator that plays critical roles in nucleotide-binding oligomerization domain 1 (NOD1), NOD2, and Toll-like receptors (TLRs) signaling. Stimulated NOD1 and NOD2 interact with RIPK2 and lead to the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPK), followed by the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12/23. Defects in NOD/RIPK2 signaling are associated with numerous inflammatory diseases, including asthma, sarcoidosis, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), multiple sclerosis, and Blau syndrome. As RIPK2 is a crucial element of innate immunity, small molecules regulating RIPK2 functions are attractive to establish novel immunotherapies. The increased interest in developing RIPK2 inhibitors has led to the clinical investigations of novel drug candidates. In this review, we attempt to summarize recent advances in the development of RIPK2 inhibitors and degraders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“formate significantly increased genes associated with Tc1 activation and differentiation, such as receptor-interacting serine/threonine-protein kinase 2 (Ripk2)64, zinc transporter ZIP8 (Slc39a8)65, furin66, poly (ADP-ribose) polymerase 1 (Parp1)67,68, ezrin (Ezr)69, and interferon regulatory factor 8 (Irf8)70–72.”
From Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy (2025) · cites this paper as [64]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591 · cited 1×
“Dysregulation of NOD/RIPK2 signaling is implicated in the development of several inflammatory diseases, including sarcoidosis, Blau syndrome, Crohn’s disease (CD), and ulcerative colitis (UC) (Hugot et al., 2001; Lesage et al., 2002; Hysi et al., 2005; McGovern et al., 2005; Tanabe et al., 2006; Stronati et al., 2008;…”
BackgroundEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964 · cited 1×
“In analogous to the EGFR T90Mmutation that renders resistance to gefitinib (Kobayashi et al., 2005), the T95M point mutation of RIPK2 in the ATP binding pocket abolished the inhibitory activities of both erlotinib and gefitinib, indicating that these compounds directly inhibited RIPK2.”
BackgroundPROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · cited 1×
“This catalytic nature of PROTACs distinguishes them from traditional inhibitors (Békés et al., 2022; Hu and Crews, 2022).”
BackgroundNod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) Detection
Girardin, S. E., Boneca, I. G., Viala, J., Chamaillard, M., Labigne, A., Thomas, G., Philpott, D. J., & Sansonetti, P. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200651200 · Cited by 2,408
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971 · cited 1×
“Modern immunotherapies focus on precisely regulating immune responses (Kany et al., 2019; McInnes and Gravallese, 2021).”
BackgroundDe-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling
Wertz, I. E., O'Rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., Wu, P., Wiesmann, C., Baker, R., Boone, D. L., et al. (2004) · Nature · doi:10.1038/nature02794 · Cited by 1,856 · cited 1×
“The deubiquitinating enzyme A20 downregulates NODs/RIPK2 signaling by removing Lys63-pUb chains from RIPK2 (Wertz et al., 2004).”
BackgroundActivation and signaling of the p38 MAP kinase pathway
ZARUBIN, T., & HAN, J. (2005) · Cell Research · doi:10.1038/sj.cr.7290257 · Cited by 1,707 · cited 1×
“The MAPK signaling pathways regulate several cellular processes, including proliferation, differentiation, inflammation, and apoptosis (Zarubin and Han, 2005; Guo et al., 2020).”
BackgroundHost Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2
Inohara, N., Ogura, Y., Fontalba, A., Gutierrez, O., Pons, F., Crespo, J., Fukase, K., Inamura, S., Kusumoto, S., Hashimoto, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c200673200 · Cited by 1,696 · cited 1×
“, 2006), whereas NOD2 is activated by muramyl dipeptide (MDP) (Girardin et al., 2003b; Inohara et al., 2003; Hasegawa et al., 2006).”
BackgroundNod1 Detects a Unique Muropeptide from Gram-Negative Bacterial Peptidoglycan
Girardin, S. E., Boneca, I. G., Carneiro, L. A. M., Antignac, A., Jéhanno, M., Viala, J., Tedin, K., Taha, M.-K., Labigne, A., Zäthringer, U., et al. (2003) · Science · doi:10.1126/science.1084677 · Cited by 1,577
ERK/MAPK signalling pathway and tumorigenesis (Review)
Guo, Y., Pan, W., Liu, S., Shen, Z., Xu, Y., & Hu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.8454 · Cited by 1,475 · cited 1×
“The MAPK signaling pathways regulate several cellular processes, including proliferation, differentiation, inflammation, and apoptosis (Zarubin and Han, 2005; Guo et al., 2020).”
Background
Cited by
Phelps, C. M., Willis, N. B., Duan, T., Lee, A. H., Zhang, Y., Rodriguez J, D. M., Pandey, S. P., Laughlin, C. R., Rosen, A. B. I., McPherson, A. C., et al. (2025) · Cell · doi:10.1016/j.cell.2025.06.018 · Cited by 91
Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives
Yang, X., Guo, H., & Zou, M. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00395-z · Cited by 92
“Aberrant activation of RIPK2 is closely associated with increased expression of signaling molecules in the colonic mucosa of IBD patients, and blocking RIPK2 activation effectively inhibits the development of experimental colitis in mice [463, 464].”
Endotoxin tolerance and trained immunity: breaking down immunological memory barriers
López‐Collazo, E., & del Fresno, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393283 · Cited by 60
Host–pathobiont interactions in Crohn’s disease
Caruso, R., Lo, B. C., Chen, G., & Núñez, G. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00997-y · Cited by 44
“A critical role of NOD2 as an intestinal microbial sensor in Crohn’s disease is further strengthened by the observation that genetic variants in RIPK2 that encode an essential kinase required for NOD2 signalling, are also linked to Crohn’s disease 69 .”
Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease
Lai, Y., Wang, X., Sun, X. F., Wu, S., Chen, X., Yang, C., Zhang, W., Yu, X., Tong, Y., Ma, F., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115647 · Cited by 24
Metadata
- Authors
- Pham, A.-T., Ghilardi, A. F., & Sun, L.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Sun, Lijun
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-07
- Volume
- 14
- Pages
- 1127722-1127722
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10028200
- OpenAlex
- W4323364425
- Cited by
- 40
- References
- 103
- Citations by year
- 2026: 9 · 2025: 13 · 2024: 11 · 2023: 7
- FWCI
- 1.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Keywords
- RIPK2, NOD2 signaling, Toll-like receptor signaling, NF-κB activation, MAPK signaling, inflammatory cytokines, inflammatory diseases, asthma, sarcoidosis, inflammatory bowel disease, multiple sclerosis, Blau syndrome, innate immunity, immunomodulation, small molecule drug candidates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.